NasdaqGS:IONSBiotechs
Why Ionis Pharmaceuticals (IONS) Is Up 5.2% After EU Approval of DAWNZERA for HAE Prevention
Ionis Pharmaceuticals and Otsuka Pharmaceutical recently secured European Commission approval for DAWNZERA™ (donidalorsen), the first RNA-targeted, self-administered therapy to prevent recurrent hereditary angioedema attacks in adults and adolescents aged 12 and older across the EU.
This decision extends the commercial reach of Ionis’s antisense technology beyond the U.S., adding a new royalty and milestone stream tied to European HAE patients.
We’ll now examine how European approval of...